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ABSTRACT Observation of molecular docking results was generally performed by analyzing the docking score and the
interacting amino acid residues separately either in tables or graphs. Sometimes it was not easy to rank the tested ligands’
docking results, especially if there were many ligands. This study aims to introduce a new way to analyze docking results
with a two‐dimensional graph between the difference in docking score and the similarity of ligand‐receptor interactions.
Molecular docking was performed with one reference ligand and several test ligands. The docking score difference was
obtained between the test and the reference ligands as the graph’s x‐axis. Meanwhile, the y‐axis contains the similarity of
ligand‐receptor interactions, obtained from the ratio of amino acid residues and the types of interactions between the test
and reference ligands. Docking result analysis was more straightforward because two critical parameters were presented in
one graph. This graph could be used to support the analysis of the docking results.
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1. Introduction
Molecular docking (or simply docking) is an in silico
method used to analyze the interactions between two
molecules. Of the two molecules, one will act as a test
compound or ligand, while the other will act as a target
or known as a receptor. In its use, the docking method is
widely used in various purposes in the field of drug design
and discovery, especially for screening in the discovery of
potential compounds with certain potential activities, as
well as to explain the mechanism of action of the inter­
actions that occur between drug compounds with known
activity against the target protein (Lin et al. 2020; Meng
et al. 2012).
Compared to several other in silico methods, molec­
ular docking is one of the most popular and widely used,
both as the primarymethod and for confirming other meth­
ods. From the beginning of 2020 to October 2020 alone,
there have been more than 10,000 articles from the Sco­
pus database published with titles, keywords, or abstracts
containing the keyword ”molecular docking.” This num­
ber is more than 1,000 articles compared to the previous
year, confirming molecular docking’s popularity. This is
mainly due to molecular docking’s various advantages, in­
cluding a brief analysis process, low cost, and guaranteed
safety because it does not use dangerous chemical reagents
(Deshpande et al. 2020; Pinzi and Rastelli 2019).
Aside from its popularity, molecular docking also
presents various challenges in its analysis. These obstacles
are generally related to the type of software used, consid­
ering that much software can be used to perform molec­
ular docking, both free and paid. Apart from the techni­
cal problems associated with the software used, one of the
biggest challenges in analyzing the docking results is the
ligand ranking based on the docking result (Pagadala et al.
2017).
Observations of molecular docking results are gen­
erally carried out by analyzing two main parameters of
the docking results separately: the docking score and
the interacting amino acid residues. These two parame­
ters are equally important in the analysis of docking re­
sults. If the docking score is often associated with lig­
and affinity for the receptor, the ligand­receptor interac­
tion becomes an indicator of whether the resulting interac­
tion can cause activity or not, compared to reference/co­
crystal ligands (Pantsar and Poso 2018; Ferreira et al.
2015). However, analyzing the two parameters simultane­
ously requires more effort, considering that one is quanti­
tative while the other is qualitative (Vieira and Sousa 2019;
Ramírez and Caballero 2016). This may not be a concern
if only a few ligands are tested, but it will cause problems
if the number of test ligands is large. The problem will
arise when presenting the data, where there will be a very
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long table to present all the data.
An approach that can be taken to facilitate the anal­
ysis of the docking results’ two parameters is to change
the ligand­receptor interaction parameters into quantita­
tive parameters so that the two parameters can be plotted as
a graph with two parameters. The rational way is to com­
pare the interacting amino acids and the types of interac­
tions in the test ligands with those shown by the reference
ligand, then expressed in terms of the percentage of simi­
larity. This approach assumes that the more similar amino
acid interactions will provide a greater chance of a similar
mechanism of action, which will result in the same activity
(Li et al. 2019; Ramírez and Caballero 2016). To the best
of our knowledge, this approach has not been previously
reported.
Based on this background, this study aims to intro­
duce a new way to analyze docking results with a two­
dimensional graph between the difference in docking score
and the similarity of ligand­receptor interactions.
2. Materials and Methods
For demonstration purposes, the docking process was per­
formed using proteins that bind to the highly selective
reference ligands, and the test ligands were compounds
known to target these proteins. These reference ligands
include a co­crystal ligand that binds to the receptor or
compounds known to interact with the receptor’s binding
site (Kolb and Irwin 2009). The docking score and the
ligand­receptor interactions will be used to compile a two­
dimensional graph between the difference in docking score
and the similarity of ligand­receptor interactions.
The protein chosen was prostaglandin G/H synthase 2
or cyclooxygenase 2 (COX­2), an enzyme as a target re­
ceptor with PDB ID 3LN1, which binds celecoxib, a selec­
tive COX­2 inhibitor. The receptor was chosen because of
the availability of co­crystal ligand that were selective to
the receptor, a high enough crystal resolution (2.40Å)with
0 Ramachandran outliers (Wang et al. 2010), the results of
redocking with low RMSD and ΔG suggesting good bind­
ing affinity (Mandour et al. 2016), and has been reported
to be used in docking studies more than 10 times in the
past three years in the Scopus database. However, this ap­




As a representative of the test ligands, 15 anti­
inflammatory compounds were used either known to act
on the COX­2 pathway (e.g., etoricoxib) or not (ac­
etaminophen, aspirin). The test ligand structure was ob­
tained from PubChem (https://pubchem.ncbi.nlm.nih.gov
/) and then downloaded in SDF format. All test ligands
were then prepared according to the method reported by
Pratama et al. (2020) then saved in .pdbqt format.
2.1.2 Receptor preparation
The receptor used in the demonstration is COX­2, which
binds to celecoxib (PDB ID 3LN1) and was downloaded
from the Protein Data Bank website (https://www.rcsb.org
/). The receptor consists of four chains (A, B, C, and D),
with the chains used for the docking process was chain A
(Wang et al. 2010). The parts of the receptors that were
not used (e.g., water, solvent, unused chains) were then
removed and given polar hydrogen as well as charges—
and finally saved in .pdbqt format using AutoDockTools
1.5.6.
2.2. Methods
2.2.1 Hardware and software
The hardware and software used in this study were the
same as the research reported by Pratama et al. (2020),
with AutoDockVina for docking andDiscovery Studio Vi­
sualizer for visualization. Two­dimensional graphical cre­
ation of ligand­receptor interactions was carried out using
Microsoft Excel 2019.
2.2.2 Validation of docking protocol
The docking protocol validation was carried out by the
redocking method reported by Morris et al. (2009). The
observed parameter was a root­mean­square deviation
(RMSD). The RMSD value less than 2 Å indicating a valid
docking protocol and can be used for the docking process.
2.2.3 Molecular docking
Docking for all test ligands performed in the same way as
the validation process with similar sizes and positions of
the grid box. The results were grouped under two param­
eters: free energy of binding (ΔG; kcal/mol) and ligand­
receptor interactions. The ligand­receptor interactions are
recorded based on two parameters: the amino acids that
interact and the types of interactions that occur. The dock­
ing process was repeated five times, and the average ΔG
value and the deviation were determined. The maximum
allowable deviation value was ±0.05 kcal/mol to avoid
high variation. The two parameters were then compared
their similarity to celecoxib as a reference ligand then the
average was calculated and expressed as a percentage.
2.2.4 Two­dimensional graph of ligand­receptor in­
teractions
The difference in ΔG values and the ligand­receptor
interactions obtained earlier was then used to create a
two­dimensional graph. The x­axis was filled with the
reduction in the ΔG value of each test ligand against
the ΔG value of the reference ligand (celecoxib). The
difference from the ΔG value of each test ligand against
ΔG celecoxib was calculated based on the following
Equation 1:
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FIGURE 1 Two‐dimensional graph outline. The further to the left and the higher the position of the test ligand, the better the ranking of the
test ligand.
∆Gdif = ∆Gtest− ∆Gref (1)
ΔGdif = the difference from the ΔG of test and reference ligand
ΔGtest = ΔG of test ligand
ΔGref = ΔG of reference ligand
The higher the difference in value, the lower the poten­
tial for affinity than the reference ligand, and vice versa.
If the difference value is negative, it indicates that the test
ligand has a higher potential for affinity than the reference
ligand.
Meanwhile, the y­axis is filled with the average per­
centage of the similarity of the amino acids that interact
and the types of interactions. The similarity of the interact­
ing amino acids was calculated by dividing the number of
amino acids interacting with both the test and the reference
ligand, divided by the total amino acids interacting with
the reference ligand. Meanwhile, the similarity of interac­
tion types is calculated by dividing the number of amino
acids with the same types of interactions for both the test
ligand and the reference ligand, divided by the number of
amino acid interactions on the reference ligand. The two
parameters were then averaged and expressed as a percent­
















%similarity = similarity of ligand­receptor interaction
nAAtest = the number of amino acids of the test ligand that also interacts
with the reference ligand
nAAref = the number of amino acids of the reference ligand
intAAtest = the number of amino acid interactions of the test ligand that
is also present in the reference ligand
intAAref = the number of amino acid interactions of the reference ligand
The number 0.5 in the ligand­receptor interaction sim­
ilarity equation shows the impact of each parameter on the
similarity of the ligand­receptor interaction. At the time
of writing, it was still unknown how the influence of the
amino acids that interact and the types of interactions that
occur on ligand­receptor interactions. The initial assump­
tion used was that the two parameters had the same effect
on the ligand­receptor interaction, so the impact weight
given was the same. This opens up opportunities for fur­
ther research regarding the comparison of the effects of
the two on ligand­receptor interactions. The two parame­
ters were then used to quantitatively express the similarity
of the ligand­receptor interactions on the y­axis, as shown
in Figure 1.
3. Results and Discussion
3.1. Validation of docking protocol
The RMSD value of the redocking process obtained was
0.857 Å, indicating that the docking protocol was valid.
The visualization of ligand overlays from redocking with
reference ligand from crystallographic results was pre­
sented in Figure 2. The redocking ligands’ appearance
shows the same orientation as the crystallographic ligands,
apart from a slight shifted in position. The results of the
FIGURE 2 Overlays of redocking ligands (blue) with reference lig‐
ands from crystallography data (green) at receptors 3LN1 with
RMSD 0.857 Å.
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FIGURE 3 Two‐dimensional graph between the difference in the value of free energy of binding and the percentage of similarity of ligand‐
receptor interactions compared to reference ligand on the 3LN1 receptor. The test ligands with the best docking results are etoricoxib (far
left) and indomethacin (topmost).
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aHydrogen bonds; bVan der Waals interaction; cPi‐sigma;
dAlkyl/Pi‐alkyl; ePi‐Pi T‐shaped/Pi‐Pi stacked/Amide‐Pi stacked
validation, alongwith the docking protocol used, were pre­
sented in Table 1. The dimensions of the grid box used
were relatively small with a size of 32 x 20 x 26 Å, ad­
justing to the size of the reference ligands, which are also
small. The redocking results showed that 24 amino acids
interacted with celecoxib. The interactions were dom­
inated by weak interactions such as Van der Waals (11
amino acids) but had considerably strong interactions such
as hydrogen bonds (six amino acids).
3.2. Molecular docking
Docking of all test ligands shows the results as predicted,
in which the ligands that were known to target COX­2,
such as etoricoxib, had the lowest AG value of ­11.4 ± 0
kcal/mol. This value is only a 1.1 kcal/mol difference from
that shown by the celecoxib from the redocking process
which is ­12.5 ± 0 kcal/mol, while the other test ligands
show a difference between 2.8 to 6.24 kcal/mol. Etori­
coxib also had a high similarity of interacting amino acid
residues with 79.17%, but interaction type was lowered
with 25%. The average of both was 52.08%, still low­
ered than some other test ligands such as indomethacin and
nimesulide, with 68.75% and 56.25%, respectively. Apart
from having the highest similarity, indomethacin also had
the second­lowest docking value after etoricoxib with ­9.7
± 0 kcal/mol, making both etoricoxib and indomethacin
the two test ligands with the closest parameter of celecoxib
as reference ligands. In other words, these two ligands
were the strongest candidates compared to other test lig­
ands. The docking of all test ligands at the binding site of
the 3LN1 receptor was presented in Table 2 and then used
to filled in the two­dimensional graph plotted previously,
as presented in Figure 3.
3.3. Discussion
The docking results were consistent with other studies re­
ported previously by Sadasivam et al. (2020), in which a
ligand such as etoricoxib, designed as a selective COX­2
inhibitor, show the highest potency compares to other lig­
ands. The docking results also show that indomethacin has
potential, although it is not a selective COX­2 inhibitor.
These results are consistent with research from Abuelizz
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et al. (2017) and Oniga et al. (2017), who reported in­
domethacin’s potency against COX­2. The 3LN1 recep­
tor selection itself was based on the consistency of results
from several previous studies (Coy­barrera 2020;Molinari
et al. 2019; Shrivastava et al. 2017). In other words, the
docking results obtained for the demonstration are appro­
priate and in line with other studies. However, there are
more interesting points to discuss.
As mentioned in the previous section, the more the
number of test ligands will cause more data to be pre­
sented. However, by presenting the docking result data
in a two­dimensional graph, the data presented is much
more concise while still presenting essential data for anal­
ysis. Readers do not have to read the entire docking re­
sults table to find the ligands with the best docking results.
Otherwise, they only need to look for the test ligand lo­
cated on the upper left of the graph to determine which test
ligand has the smallest difference in docking values and
the highest ligand­receptor interaction similarity with the
reference ligand. This also makes the presentation of the
results shorter even though the number of ligands tested
is immense, considering that the graph space remains the
same and does not depend on the number of test ligands.
There are times when the ligands with the smallest
docking score difference and the highest ligand­receptor
interaction similarity compared to reference ligands are
two different test ligands, as presented in the results of
this study (etoricoxib and indomethacin). In that case,
the recommendations that can be given for both, consid­
ering these two parameters are equally crucial in molec­
ular docking. It has been occasionally reported that the
test ligand with the best docking score has an unstable in­
teraction with the receptor when tested by molecular dy­
namics, compared to the test ligand with a ligand­receptor
interaction closer to the ligand reference (Lam et al. 2018;
Salmaso and Moro 2018).
One of the essential points in presenting the docking
results in this two­dimensional graph is the obligation to
provide reference ligands for comparison, considering that
some of the receptors available in the protein data bank are
apo­receptors (Forli et al. 2016). For new target receptors
for which no proven reference ligands have been found,
it is not possible to present the docking results in a two­
dimensional graph. Under these conditions, it is highly
recommended to conduct in vitro and in vivo studies first
to ensure that the reference ligand to be used is proven.
This two­dimensional graph has been used before to
present the docking results of several types of receptors
(Pratama et al. 2020, 2021). Research by Pratama et al.
(2020) even presents the docking results of two receptors
TABLE 2 Results of the docking of all test ligands at the binding site of the 3LN1 receptor.
Ligand Act Asp Cln Dcl Etr Ibp Ind Ktp Ktr Mfn Mlx Npr Nms Phn Prx
ΔG±SD (kcal/mol) ‐6.26 ± 0.05 ‐6.4 ± 0 ‐8.5 ± 0 ‐8.72 ± 0.04 ‐11.4 ± 0 ‐7.7 ± 0 ‐9.7 ± 0 ‐9.44 ± 0.05 ‐9.08 ± 0.04 ‐8.92 ± 0.04 ‐8.8 ± 0 ‐8.3 ± 0 ‐9.1 ± 0 ‐8.1 ± 0 ‐9.2 ± 0
Amino acid residues 75‐Hisa ‐ 75‐Hisf ‐ 75‐Hisa 75‐Hisa 75‐Hisa 75‐Hisa 75‐Hisa 75‐Hisf 75‐Hisf 75‐Hisb 75‐Hisb 75‐Hisf
‐ ‐ ‐ ‐ ‐ ‐ 102‐Vala ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
‐ ‐ ‐ 106‐Argb ‐ ‐ 106‐Arga ‐ ‐ ‐ ‐ ‐ 106‐Argb 106‐Arga ‐
178‐Glna ‐ ‐ ‐ 178‐Glna ‐ ‐ 178‐Glna ‐ ‐ ‐ ‐ ‐ ‐ ‐
‐ 334‐Tyra 334‐Tyra ‐ ‐ 334‐Tyrf ‐ ‐ 334‐Tyra 334‐Tyra ‐ 334‐Tyra ‐ ‐ ‐
335‐Vala 335‐Vala 335‐Valf 335‐Valf 335‐Valf 335‐Valf 335‐Valf 335‐Vala 335‐Valf 335‐Valf 335‐Vala 335‐Vala 335‐Vala 335‐Valf 335‐Vala
338‐Leub 338‐Leua 338‐Leuf 338‐Leua 338‐Leua 338‐Leuf 338‐Leuf 338‐Leuf 338‐Leuc 338‐Leuf 338‐Leua 338‐Leuf 338‐Leuf 338‐Leuf 338‐Leua
339‐Serb 339‐Sera 339‐Sera 339‐Sera 339‐Serc 339‐Sera 339‐Sera 339‐Serc 339‐Serc 339‐Sera 339‐Serc 339‐Serc 339‐Serb 339‐Sera 339‐Sera
340‐Glya ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
341‐Tyra ‐ 341‐Tyrf 341‐Tyrb 341‐Tyrf 341‐Tyrb 341‐Tyra 341‐Tyra 341‐Tyra 341‐Tyrf 341‐Tyra 341‐Tyra 341‐Tyra 341‐Tyra 341‐Tyra
‐ ‐ ‐ ‐ 345‐Leuf ‐ 345‐Leua ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
‐ 367‐Phea 367‐Phea 367‐Phea ‐ 367‐Phea 367‐Phef ‐ 367‐Phea 367‐Phea 367‐Phea 367‐Phea ‐ 367‐Phea 367‐Phea
‐ 370‐Leua 370‐Leua 370‐Leua 370‐Leua 370‐Leua 370‐Leuf ‐ 370‐Leua 370‐Leua 370‐Leua ‐ 370‐Leua 370‐Leuf 370‐Leua
‐ 371‐Tyrb 371‐Tyra 371‐Tyra ‐ 371‐Tyrf 371‐Tyrf ‐ 371‐Tyrb 371‐Tyrb 371‐Tyra 371‐Tyra ‐ 371‐Tyrf 371‐Tyra
‐ 373‐Trpd 373‐Trpa 373‐Trpa 373‐Trpa 373‐Trpf 373‐Trpd 373‐Trpa 373‐Trpa 373‐Trpd 373‐Trpa ‐ 373‐Trpa 373‐Trpf 373‐Trpa
499‐Argb ‐ ‐ ‐ 499‐Argb 499‐Argb 499‐Arga 499‐Argb 499‐Arga ‐ 499‐Arga 499‐Arga 499‐Arga ‐ 499‐Arga
502‐Alaa ‐ ‐ ‐ 502‐Alaa 502‐Alaa 502‐Alaa 502‐Alaa 502‐Alaa ‐ 502‐Alaf 502‐Alaa 502‐Alaa ‐ 502‐Alaa
503‐Ilea ‐ ‐ ‐ 503‐Ilea 503‐Ilea ‐ 503‐Ilea 503‐Ilea ‐ ‐ ‐ 503‐Ilea ‐ 503‐Ilea
504‐Phea 504‐Phea 504‐Phef 504‐Phef 504‐Phea 504‐Phea 504‐Phea 504‐Pheb 504‐Phef 504‐Phef 504‐Phee 504‐Phea 504‐Phed 504‐Phef 504‐Phea
‐ 508‐Mete 508‐Metb 508‐Metf 508‐Metb ‐ 508‐Meta 508‐Meta 508‐Meta 508‐Mete 508‐Meta ‐ 508‐Meta 508‐Metf 508‐Meta
509‐Valc 509‐Vala 509‐Valf 509‐Valc 509‐Valc 509‐Valf 509‐Valc 509‐Valc 509‐Valc 509‐Valc 509‐Valc 509‐Valc 509‐Valc 509‐Valc 509‐Valf
‐ 512‐Glya 512‐Glya 512‐Glyd 512‐Glya 512‐Glya 512‐Glya 512‐Glya 512‐Glya 512‐Glya 512‐Glyd 512‐Glya 512‐Glya 512‐Glya 512‐Glyd
513‐Alaa 513‐Alaa 513‐Alaf 513‐Alaf 513‐Alaa 513‐Alaa 513‐Alaf ‐ 513‐Alaa 513‐Alaf 513‐Alaa 513‐Alaf 513‐Alaa 513‐Alac 513‐Alaa
‐ 516‐Serb 516‐Serb 516‐Sera 516‐Sera 516‐Sera 516‐Sera ‐ 516‐Serb 516‐Serb 516‐Serb 516‐Sera 516‐Serb 516‐Serb





54.17 54.17 62.5 66.67 79.17 70.83 87.5 58.33 75 62.5 75 62.5 75 66.67 75
The similarity








43.75 29.17 35.42 45.83 52.08 50 68.75 43.75 50 37.5 50 47.92 56.25 47.92 50
Act: acetaminophen; Asp: aspirin; Cln: clonixin; Dcl:diclofenac; Etr: etoricoxib; Ibp: ibuprofen; Ind: indomethacin; Ktp: ketoprofen; Ktr: ketorolac; Mfn: mefenamic acid; Mlx: meloxicam; Npr: naproxen; Nms: nimesulide;
Phn: phenylbutazone; Prx: piroxicam; aVan der Waals interaction; bHydrogen bonds; cPi‐sigma; dPi‐Pi T‐shaped/Pi‐Pi stacked/Amide‐Pi stacked; ePi‐sulfur; fAlkyl/Pi‐alkyl; *(Similarity of amino acids + similarity in type of
interaction)/2
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in one graph simultaneously by providing different color
dots, showing the advantage that this two­dimensional
graph can be used to present the docking results of multi­
ple receptors at once. This is advantageous because it can
streamline research reports, considering that some studies
with molecular docking are carried out at more than one
receptor, while some scientific journals impose limits on
the number of supporting illustrations such as tables and
figures in the manuscript. Thus, it is expected that the pre­
sentation of docking results in this two­dimensional graph
can become a new trend in the presentation of docking re­
sults.
Apart from its simplicity, two things can still be im­
proved in the presentation with these two­dimensional
graphics. First, given that some of the test ligands can
have very similar docking scores and ligand­receptor in­
teractions often due to similar structures (Gimeno et al.
2019), it is possible that some ligands are very close to­
gether and even overlap on the graph. An enlarged version
of the graph is required to overcome the above mentioned
in the area where the ligands overlap. Second, as previ­
ously described, the calculation between the similarity of
the interacting amino acids and the types of interactions
averaged is assumed to have the same impact. Meanwhile,
no previous research has proven and calculated these two
parameters’ impact on the docking results. Hence, there is
an opportunity for further research on how to compare the
impact of the two parameters on docking results, whether
they have the same impact or whether one has more impact
than the other.
4. Conclusions
The two­dimensional graph between the difference in
docking score and the similarity of ligand­receptor inter­
actions can support the analysis of the docking results by
presenting the docking results briefly.
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